The present preclinical study characterized the effects of zalfermin, a novel long-acting FGF21 analog, alone and in combination with semaglutide in the AMLN DIO-MASH mouse, a well-established biopsy-confirmed model of MASH and fibrosis [19,20]. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.